
## **Supplementary Information**

Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy


Takuya Iino<sup>1,2</sup>, PhD; Manabu Nagao<sup>3</sup>\*, MD, PhD; Hidekazu Tanaka<sup>1</sup>, MD, PhD; Sachiko Yoshikawa<sup>1</sup>, MD, PhD; Junko Asakura<sup>1</sup>, MD, PhD; Makoto Nishimori<sup>4</sup>, MD, PhD; Masakazu Shinohara<sup>4,5</sup>, MD, PhD; Amane Harada<sup>2</sup>, PhD; Shunsuke Watanabe<sup>6</sup>, Tatsuro Ishida<sup>1,7</sup>, MD, PhD; Ken-ichi Hirata<sup>1,3</sup>, MD, PhD; Ryuji Toh<sup>3</sup>, MD, PhD.

- 1. Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
- 2. Central Research Laboratories, Sysmex Corporation, Kobe, Japan
- 3. Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
- 4. Division of Molecular Epidemiology, Kobe University Graduate School of Medicine, Kobe, Japan
- 5. The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Kobe, Japan
- 6. Bio-Diagnostic Reagent Technology Center, Sysmex Corporation, Kobe, Japan
- Division of Nursing Practice, Kobe University Graduate School of Health Sciences, Kobe, Japan



Supplementary Figure S1. Effects of Each Concentrations of Urea for TTR Stability

The residual TTR tetramer formation ratio after urea-induced denaturation of recombinant wild-type TTR, recombinant T119M TTR, recombinant V30M TTR, and recombinant V122I TTR. The urea concentrations used were 0.8 M (A), 1.6 M (B), 2.4 M (C), 3.2 M (D), 4.8 M (E), and 6.4 M (F). Values are expressed as the means  $\pm$  SDs (n = 6). \*\* p < 0.01, \*\*\* p < 0.001 compared to the WT group. Data were analyzed by one-way ANOVA with Dunnett's multiple comparisons test (A-D, F) or by Kruskal-Wallis test, followed by Dunn's post-test (E). TTR, transthyretin; WT, wild-type;



## Supplementary Figure S2. Correlation Between ELISA and Immunoturbidimetry

The correlation between the quantitative results of TTR in plasma samples measured by

ELISA and immunoturbidimetry(n=40).

TTR (ng/mL)	Luminescence intensity				
	TTR purified from plasma	Recombinant Wild type TTR	Recombinant F87M/L110M TTR		
10	18874.5	17017.5	1479.0		
5	9744.5	9461.5	964.0		
2.5	5248.5	5055.5	661.0		
1.25	2959.0	2901.0	470.0		
0.625	1751.0	1733.0	400.0		
0.3125	1086.5	1218.0	402.0		
0.15625	807.0	858.0	383.5		
0.078125	712.0	672.0	405.0		
0.0390625	424.5	410.0	406.0		
0.0195313	432.0	397.5	358.0		
0.0097656	372.5	383.5	398.0		
0	335.5	329.0	351.0		

## Supplementary Table 1. Detailed ELISA data

TTR (ng/mL)	%CV	Accuracy %
10	4.1	87.8
5	2.4	99.0
2.5	2.3	107.3
1.25	4.9	101.8
0.625	4.8	98.9
0.3125	10.5	89.6

Supplementary Table 2. Calibration curve analysis.

## Supplementary Table 3. Dilution linearity of serum

Dilution factor	Measured concentration	Dilution-corrected concentration	% Change	
	(ng/mL)	(ng/mL)		
40000	6.39	-	-	
80000	3.53	3.19	110.6	
160000	1.82	1.77	103.0	
320000	0.86	0.91	94.4	
640000	0.40	0.43	92.9	

	<u>Intra-assay (n = 6)</u>			Inter-assay $(n=6)$		
	Mean, ng/mL	SD	%CV	Mean, ng/mL	SD	%CV
High	8.3	0.1	1.1	8.0	0.6	7.8
Medium	4.8	0.1	2.2	4.5	0.3	7.0
Low	2.4	0.1	2.5	2.3	0.1	5.2

Supplementary Table 4. Intra- and inter-assay precision